BRPI0713501A2 - composições antibacterianas - Google Patents

composições antibacterianas Download PDF

Info

Publication number
BRPI0713501A2
BRPI0713501A2 BRPI0713501-7A BRPI0713501A BRPI0713501A2 BR PI0713501 A2 BRPI0713501 A2 BR PI0713501A2 BR PI0713501 A BRPI0713501 A BR PI0713501A BR PI0713501 A2 BRPI0713501 A2 BR PI0713501A2
Authority
BR
Brazil
Prior art keywords
alkyl
hydrogen
optionally substituted
antibacterial compositions
antibacterial
Prior art date
Application number
BRPI0713501-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryall Haydon David
George Czaplewski Llody
John Palmer Nicholas
Robert Mitchell Dale
Frederick Atherall John
Richard Steele Christopher
Ladduwahetty Tamara
Original Assignee
Prolysis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolysis Ltd filed Critical Prolysis Ltd
Publication of BRPI0713501A2 publication Critical patent/BRPI0713501A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0713501-7A 2006-06-22 2007-06-21 composições antibacterianas BRPI0713501A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0612428.3A GB0612428D0 (en) 2006-06-22 2006-06-22 Antibacterial agents
GB0612428.3 2006-06-22
PCT/GB2007/002314 WO2007148093A1 (en) 2006-06-22 2007-06-21 Antibacterial compositions

Publications (1)

Publication Number Publication Date
BRPI0713501A2 true BRPI0713501A2 (pt) 2012-03-13

Family

ID=36803739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713501-7A BRPI0713501A2 (pt) 2006-06-22 2007-06-21 composições antibacterianas

Country Status (21)

Country Link
US (2) US7977340B2 (OSRAM)
EP (1) EP2034997B1 (OSRAM)
JP (1) JP5309021B2 (OSRAM)
KR (1) KR101443795B1 (OSRAM)
CN (1) CN101472585B (OSRAM)
AU (1) AU2007262791B2 (OSRAM)
BR (1) BRPI0713501A2 (OSRAM)
CA (1) CA2655403C (OSRAM)
DK (1) DK2034997T3 (OSRAM)
EA (1) EA019748B1 (OSRAM)
ES (1) ES2403005T3 (OSRAM)
GB (1) GB0612428D0 (OSRAM)
IL (1) IL195687A (OSRAM)
MX (1) MX2008015706A (OSRAM)
MY (1) MY148682A (OSRAM)
NZ (1) NZ574313A (OSRAM)
PL (1) PL2034997T3 (OSRAM)
PT (1) PT2034997E (OSRAM)
SG (1) SG172676A1 (OSRAM)
WO (1) WO2007148093A1 (OSRAM)
ZA (1) ZA200900240B (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
JP2010511682A (ja) 2006-12-04 2010-04-15 アストラゼネカ アクチボラグ 抗菌性の多環系尿素化合物
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
EP2321309A1 (en) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
EP2277870A1 (de) * 2009-06-24 2011-01-26 Bayer CropScience AG Substituierte Benzoxa(thia)zole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2012146246A (ru) 2010-03-31 2014-05-10 Актелион Фармасьютиклз Лтд Антибактериальные производные изохинолин-3-илмочевины
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
AU2011260097B2 (en) 2010-06-01 2015-01-22 Summit (Oxford) Limited Compounds for the treatment of clostridium difficile associated disease
CA2824519C (en) 2011-01-14 2020-06-16 Vertex Pharmaceuticals Incorporated Process of making gyrase and topoisomerase inhibitors
JP6085829B2 (ja) 2011-01-14 2017-03-01 スペロ トリネム, インコーポレイテッド ピリミジンジャイレースおよびトポイソメラーゼiv阻害剤
TW201309676A (zh) 2011-01-14 2013-03-01 Vertex Pharma 旋轉酶抑制劑(r)-1-乙基-3-[5-[2-(1-羥基-1-甲基-乙基)嘧啶-5-基]-7-(四氫呋喃-2-基]-1h-苯并咪唑-2-基]脲之固體形式
EP2663562B1 (en) 2011-01-14 2018-11-07 Spero Trinem, Inc. Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
TWI554515B (zh) 2011-06-20 2016-10-21 維泰克斯製藥公司 旋轉酶(gyrase)及拓樸異構酶抑制劑之磷酸酯
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014087431A1 (en) * 2012-12-09 2014-06-12 Council Of Scientific & Industrial Research One pot process for the conversion of aroyl chlorides to acyl thioureas
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
JP2017504662A (ja) 2014-02-03 2017-02-09 スペロ ジャイレース インク ポリミキシンを含む抗菌剤の組合せ
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン, インコーポレイテッド 抗線維性ピリジノン
EP3227301A1 (de) * 2014-12-02 2017-10-11 Bayer CropScience AG Bicyclische verbindungen als schädlingsbekämpfungsmittel
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
CA3015768A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
JP7098630B2 (ja) 2017-01-10 2022-07-11 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
KR20190133667A (ko) 2017-03-24 2019-12-03 다이쇼 세이야꾸 가부시끼가이샤 2(1h)-퀴놀리논 유도체
CA3058183A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
US20220289705A1 (en) 2019-07-17 2022-09-15 Summit (Oxford) Limited Process for the preparation of ridinilazole and crystalline forms thereof
CN116033828B (zh) 2020-07-02 2025-05-16 拜耳公司 作为害虫防治剂的杂环衍生物
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
CN116444376B (zh) * 2023-04-19 2024-01-26 德兴市德邦化工有限公司 一种3,5-二氯硝基苯的生产工艺
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides
CN119350937B (zh) * 2024-10-30 2025-08-12 广东豪之盛新材料有限公司 一种双组份气雾喷漆及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810988A (en) * 1968-11-01 1974-05-14 Ciba Geigy Ag Control of phytopathogenic fungi with n-benzothiazae-2-yl n-{40 {11 propylure
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
CN1422262A (zh) * 2000-02-07 2003-06-04 艾博特股份有限两合公司 2-苯并噻唑基脲衍生物及其作为蛋白激酶抑制剂的应用
KR100526487B1 (ko) 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
ES2331250T3 (es) * 2000-12-15 2009-12-28 Vertex Pharmaceuticals Incorporated Inhibidores de la girasa bacteriana y usos de los mismos.
AR042956A1 (es) * 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
WO2005037845A1 (en) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents

Also Published As

Publication number Publication date
JP5309021B2 (ja) 2013-10-09
EA019748B1 (ru) 2014-06-30
WO2007148093A1 (en) 2007-12-27
CN101472585B (zh) 2013-12-04
PT2034997E (pt) 2013-01-24
IL195687A (en) 2013-12-31
NZ574313A (en) 2011-10-28
AU2007262791B2 (en) 2012-11-08
US20110263590A1 (en) 2011-10-27
MX2008015706A (es) 2009-03-31
KR20090029817A (ko) 2009-03-23
US7977340B2 (en) 2011-07-12
IL195687A0 (en) 2009-09-01
ZA200900240B (en) 2009-12-30
US8389516B2 (en) 2013-03-05
CN101472585A (zh) 2009-07-01
EP2034997A1 (en) 2009-03-18
CA2655403A1 (en) 2007-12-27
JP2009541289A (ja) 2009-11-26
GB0612428D0 (en) 2006-08-02
DK2034997T3 (da) 2013-02-11
EP2034997B1 (en) 2012-10-17
SG172676A1 (en) 2011-07-28
PL2034997T3 (pl) 2013-04-30
KR101443795B1 (ko) 2014-10-21
ES2403005T3 (es) 2013-05-13
MY148682A (en) 2013-05-31
US20090197877A1 (en) 2009-08-06
EA200900047A1 (ru) 2009-06-30
AU2007262791A1 (en) 2007-12-27
CA2655403C (en) 2014-02-04

Similar Documents

Publication Publication Date Title
BRPI0713501A2 (pt) composições antibacterianas
BR0316496A (pt) Quinolin-, isoquinolin-, e quinazolin-oxialquilamidas e seu emprego como fungicidas
FR2865135B1 (fr) Installation de sterilisation d'articles par bombardement electronique
BRPI0811198A8 (pt) Fosfatase alcalina direcionada a osso, kits e métodos de seu uso
BRPI0518301A2 (pt) inseticidas
BRPI0411528A (pt) uso de isomalte como prebiótico
EA201000993A1 (ru) Конденсированные тиазолы, обладающие антибактериальными свойствами
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
CR9375A (es) Derivados de ciclopropanocarboxamida
MX2009003129A (es) Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
BRPI0413467A (pt) aminopironas e seu uso como inibidoras da atm
BRPI0607220B8 (pt) dispositivo de proteção auricular com material de amortecimento
IL190972A0 (en) Updating multiple levels of translation lookaside buffers (tlbs) field
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
ATE505083T1 (de) Fungizide mischungen
BR0113970A (pt) Compostos de pirimidina e seu uso
SV2009002927A (es) Combinacion fungicidas de principios activos
CR11340A (es) Mezclas fungicidas de triticonazol y difenoconazol
ATE528284T1 (de) Metallcarbamate aus tolylendiaminen
CR8177A (es) Compuestos de 3- arilpiridina arilcondensados y su empleo para combatir hongos nocivos
BRPI0415285A (pt) derivados de aminoalcanol
BRPI0408467A (pt) cromenonaindóis
ECSP109874A (es) Nuevos compuestos 892
ITMI20050730A1 (it) Preparazione di composizioni con elevata attivita'insetticida

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BIOTA EUROPE LIMITED (GB)

Free format text: TRANSFERIDO DE: PROLYSIS LIMITED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.